Mitchell D. Nambu

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

J. Jean Cui, Michelle Tran‐Dubé, Hong Shen et al. · Journal of Medicinal Chemistry · 2011 · 905 citations · Full text

Drug Target, Lead Series, Chemical Biology +20

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Cancer Research · 2007 · 746 citations · Full text

Tumor Biology, C-met Kinase, Chemoprevention Strategy +15

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 <i>H</i> -[1,2,3]triazolo[4,5- <i>b</i> ]pyrazin-6-yl)-1 <i>H</i> -pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer

J. Jean Cui, Michele McTigue, Mitchell D. Nambu et al. · Journal of Medicinal Chemistry · 2012 · 103 citations · Full text

Lessons from (<i>S</i>)-6-(1-(6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats

J. Jean Cui, Hong Shen, Michelle Tran‐Dubé et al. · Journal of Medicinal Chemistry · 2013 · 39 citations · Full text

Compound 8, Chemoprevention Strategy, Cardiovascular Pharmacology +22

4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

Kevin K.‐C. Liu, Shubha Bagrodia, Simon Bailey et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 33 citations · Full text

Medicine, Mechanism Of Action, Pharmacological Agent +3